|
?:authorAffiliation
|
-
[\'Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), 10903 New Hampshire Avenue, Silver Spring, MD 20871, USA.\', \'Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA.\', \'Division of Pulmonary and Critical Care, Department of Internal Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.\', \'Department of Pharmacy, University of Maryland Medical Center, Baltimore, MD, USA.\', \'Division of Infectious Disease, Department of Internal Medicine, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD USA.\', \'University of Maryland School of Medicine, Baltimore, MD USA.\', \'University of Maryland Medical Center, Baltimore, MD USA.\', \'Department of Obstetrics and Gynecology, University of Maryland School of Medicine, Baltimore, MD, USA.\', \'Department of Medicine, Program in Trauma, University of Maryland School of Medicine, Baltimore, MD, USA.\', \'Emerging Pathogens Section, Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD, USA; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.\', \'Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD USA.\', \'Department of Medicine, Baltimore VA Medical Center, Baltimore, MD 21201, USA.\', \'National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD USA.\', \'Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), 10903 New Hampshire Avenue, Silver Spring, MD 20871, USA. Electronic address: Surender.Khurana@fda.hhs.gov.\']
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}